期刊
NEUROSCIENCE LETTERS
卷 690, 期 -, 页码 178-180出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2018.10.040
关键词
Neuroprotection; Dopaminergic MN9D cells; miRNA upregulation
资金
- Texas Tech University Health Sciences Center El Paso Graduate School of Biomedical Sciences
- Fogarty International Center - U.S./Costa Rica Neuropsychiatric Genetics Research Training Program [NCOD-5D43TW008333]
- Hoy Family Research
- Perez Family Research
- Lizanell and Colbert Coldwell Foundation
- Ms. Anna Mae Doyle Gift Funds
- Multiple System Atrophy (MSA) Coalition
- El Paso Community Foundation
In searching for Parkinson's disease (PD) pharmacotherapies we began studying FTY720, a food and drug administration (FDA) approved drug. We also created derivatives, FTY720-C2 and FTY720-Mitoxy, and began assessing them. Here we treated dopaminergic MN9D cells with FTY720s then measured microRNA (miRNA) levels by PCR arrays. We discovered that all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p. Investigations revealed that some miRNAs downregulate alpha-synuclein, while others reduce apoptosis, suggesting that FTY720s may act to reduce synucleinopathy and dopaminergic neuron loss in PD and related disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据